PEG and PEGylation: A Historical Review of Their Evolution

Added:

Anti-PEG Immunogenicity and the Limitations of Non-Biodegradable Polymers

While PEGylation has long been the gold standard for improving drug delivery, growing scientific evidence highlights significant limitations of Polyethylene Glycol (PEG). First, PEG is not biodegradable, raising concerns regarding its long-term accumulation in tissues and organs, which can cause cellular vacuolation. Second, PEG is not immunologically inert. Widespread exposure to PEG in consumer and medical products has led to a high prevalence of pre-existing anti-PEG antibodies in the general population. These antibodies can trigger the 'accelerated blood clearance' (ABC) phenomenon, which rapidly clears PEGylated therapeutics from the body and diminishes their efficacy. Furthermore, anti-PEG antibodies can cause severe hypersensitivity reactions, including anaphylaxis. These drawbacks have driven an active shift in biomaterials research toward alternative 'stealth' platforms. Researchers are increasingly turning to biodegradable or less immunogenic alternatives, such as zwitterionic polymers, polyoxazolines, and recombinant polypeptides (like PASylation), challenging the long-held assumption that PEG is the optimal choice for drug delivery systems.

Basic polymer chemistry, including the concepts of monomers, polymer chains, and molecular weight distribution.
Fundamental concepts in pharmacokinetics, specifically drug clearance, half-life, and biodistribution.
An understanding of protein structure and how therapeutic proteins interact with the human immune system.
The concept of biocompatibility and how the body identifies and clears foreign substances via opsonization.
Advanced conjugation chemistry, such as site-specific PEGylation and the use of click chemistry linkers.
Alternative polymer technologies designed to overcome PEG-related immunogenicity, such as PASylation, XTEN, and zwitterionic polymers.
The role of PEGylated lipid nanoparticles (LNPs) in modern mRNA vaccine delivery and gene therapy.
Clinical and regulatory challenges of PEGylated therapeutics, including the development of anti-PEG antibodies in patients.
4.9K views61likes28:53@ElsevierpublishingOriginal Release: 2017-08-04

PEGylation, the process of attaching polyethylene glycol (PEG) to biomolecules, was pioneered by Frank Davis in the late 1960s to reduce immunogenicity of recombinant protein drugs by making them appear less foreign to the immune system; this technology evolved from separate research threads in drug delivery and biomaterials surfaces, eventually becoming a multi-billion dollar industry with blockbuster drugs like PEG interferon and PEG granulocyte colony-stimulating factor, though recent discoveries of anti-PEG antibodies have prompted exploration of alternative polymers such as zwitterions and polyoxazolines to address immune recognition issues.